Halozyme Therapeutics Inc (HALO)

Pretax margin

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Earnings before tax but after interest (EBT)	US$ in thousands	557,132	348,329	248,918	248,518	129,302
Revenue	US$ in thousands	1,015,320	829,253	660,116	443,310	267,594
Pretax margin		54.87%	42.01%	37.71%	56.06%	48.32%

December 31, 2024 calculation

Pretax margin = EBT ÷ Revenue
= $557,132K ÷ $1,015,320K
= 54.87%

Halozyme Therapeutics Inc's pretax margin has shown variability over the years based on the provided data. The pretax margin increased from 48.32% in December 31, 2020, to 56.06% in December 31, 2021, indicating improved profitability before considering taxes. However, the margin declined to 37.71% in December 31, 2022, suggesting a decrease in the company's ability to generate profits before tax expenses during that period.

Subsequently, there was a moderate recovery as the pretax margin rose to 42.01% in December 31, 2023, reflecting some improvement in profitability compared to the previous year. Finally, the pretax margin increased substantially to 54.87% by December 31, 2024, pointing towards a significant enhancement in the company's profit generation before tax considerations.

The fluctuation in Halozyme Therapeutics Inc's pretax margin over the years may indicate changes in the company's cost structure, revenue generation, efficiency in operations, or other external factors impacting its profitability. It would be essential for stakeholders to closely monitor these trends and understand the underlying reasons for any significant shifts in the pretax margin to assess the company's overall financial health and performance.